Literature DB >> 8740124

Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.

B Wilske1, U Busch, V Fingerle, S Jauris-Heipke, V Preac Mursic, D Rössler, G Will.   

Abstract

Borrelia burgdorferi sensu lato, the etiological agent of Lyme borreliosis is considerably heterogeneous in Europe. Since the outer surface proteins OspA and OspC are the most promising candidates for a Borrelia vaccine the immunological heterogeneity of these proteins was investigated. By immunological analysis with monoclonal antibodies and sequence analysis of PCR amplified OspA and OspC at least seven and 16 different types, respectively, were found. Whereas skin isolates (n = 68) were quite homogeneous (84% belonged to OspA-serotype 2 or Borrelia afzelii), isolates from human cerebrospinal fluid and from ticks (n = 43 and n = 90 respectively) were highly heterogeneous in their OspA-serotypes with prevalence of the Borrelia garinii associated types (about 70%). OspA-type 4 was often found among isolates from cerebrospinal fluid (28%). In ticks type 4 OspA has not been detected by culture so far. However, as reported in a previous study, type 4 OspA could be detected in ticks by the highly sensitive PCR technique.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740124     DOI: 10.1007/bf01713341

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

2.  Antigenic variability of Borrelia burgdorferi.

Authors:  B Wilske; V Preac-Mursic; G Schierz; R Kühbeck; A G Barbour; M Kramer
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody.

Authors:  A G Barbour; S L Tessier; W J Todd
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

4.  An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis.

Authors:  B Wilske; V Preac-Mursic; U B Göbel; B Graf; S Jauris; E Soutschek; E Schwab; G Zumstein
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.

Authors:  B Wilske; V Preac-Mursic; S Jauris; A Hofmann; I Pradel; E Soutschek; E Schwab; G Will; G Wanner
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.

Authors:  S D Lovrich; S M Callister; B K DuChateau; L C Lim; J Winfrey; S P Day; R F Schell
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

7.  Recombinant immunoblot in the serodiagnosis of Lyme borreliosis. Comparison with indirect immunofluorescence and enzyme-linked immunosorbent assay.

Authors:  B Wilske; V Fingerle; P Herzer; A Hofmann; G Lehnert; H Peters; H W Pfister; V Preac-Mursic; E Soutschek; K Weber
Journal:  Med Microbiol Immunol       Date:  1993-11       Impact factor: 3.402

8.  Molecular characterization of Borrelia burgdorferi sensu lato strains by pulsed-field gel electrophoresis.

Authors:  U Busch; C H Teufel; R Boehmer; B Wilske; V Preac-Mursic
Journal:  Electrophoresis       Date:  1995-05       Impact factor: 3.535

9.  Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis.

Authors:  A P van Dam; H Kuiper; K Vos; A Widjojokusumo; B M de Jongh; L Spanjaard; A C Ramselaar; M D Kramer; J Dankert
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

10.  [Immunochemical analysis of the immune response in late manifestations of Lyme borreliosis].

Authors:  B Wilske; V Preac-Mursic; G Schierz; W Gueye; P Herzer; K Weber
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-03
View more
  31 in total

1.  Prevalence and incidence of antibodies to Borrelia burgdorferi and to tick-borne encephalitis virus in agricultural and forestry workers from Tuscany, Italy.

Authors:  P Tomao; L Ciceroni; M C D'Ovidio; M De Rosa; N Vonesch; S Iavicoli; S Signorini; S Ciarrocchi; M G Ciufolini; C Fiorentini; B Papaleo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

2.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

3.  Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development.

Authors:  Eric L Buckles; Christopher G Earnhart; Richard T Marconi
Journal:  Clin Vaccine Immunol       Date:  2006-10

4.  Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.

Authors:  Christopher G Earnhart; Eric L Buckles; John Stephen Dumler; Richard T Marconi
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.

Authors:  Rhonda L LaFleur; Steven M Callister; Jennifer C Dant; Terri L Wasmoen; Dean A Jobe; Steven D Lovrich
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

6.  Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys.

Authors:  G H Giambartolomei; V A Dennis; M T Philipp
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

7.  Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.

Authors:  G Wang; C Ojaimi; R Iyer; V Saksenberg; S A McClain; G P Wormser; I Schwartz
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 8.  Biology of infection with Borrelia burgdorferi.

Authors:  Kit Tilly; Patricia A Rosa; Philip E Stewart
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

9.  Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

Authors:  Rhonda L LaFleur; Jennifer C Dant; Terri L Wasmoen; Steven M Callister; Dean A Jobe; Steven D Lovrich; Thomas F Warner; O Abdelmagid; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

10.  Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant Borrelia garinii OspA serotype 4.

Authors:  Nathalie D van Burgel; Peter Kraiczy; Tim J Schuijt; Peter F Zipfel; Alje P van Dam
Journal:  BMC Microbiol       Date:  2010-02-10       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.